What changed
2026-08-04 17:47 UTC → 2026-08-05 19:44 UTC ·
added
removed
Eli Lilly retatrutide obesity trials & early trials, access & market backdrop
In late Late July 2026 Eli Lilly released topline data from its Phase III obesity studies TRIUMPH‑2 and TRIUMPH‑3, showing adults with type‑2 diabetes and obesity lost TRIUMPH‑3 showed retatrutide induced up to 20.8 22.6 % of body weight after 80 weeks and participants loss in severely obese adults with severe obesity and cardiovascular disease lost up to 22.6 %. The trials reported disease, alongside improvements in glycaemic control, lipids, blood pressure and inflammatory markers, with a non‑significant trend toward fewer major cardiovascular events versus placebo. markers. The most common adverse events were gastrointestinal (nausea, diarrhoea, constipation). The company said it would seek a biologics‑license application with the U.S. FDA in the first quarter of 2027, after completing additional manufacturing and quality‑control verifications. gastrointestinal. On 4 August 2026 Lilly announced an early‑access (compassionate‑use) program for retatrutide, a compassionate‑use program, initially limited to patients with serious unmet medical needs who cannot join ongoing trials. The program will broaden eligibility, allowing and later broadened to allow more patients severely obese adults in the United States to apply while regulatory review continues. Lilly reiterated its plan to file for FDA approval review continues, with a planned biologics‑license submission in early 2027. The move follows reports of growing black‑market interest early‑access rollout comes as Lilly’s GLP‑1 portfolio, especially Mounjaro, experiences rapid market expansion. Global Mounjaro sales doubled to $18.6 billion in the unapproved drug. Analysts continue first half of 2026 and the company extended its LillyDirect home‑delivery service to view retatrutide as all UK private weight‑management pharmacies. Analysts note that the growing demand for GLP‑1 agents has sparked safety discussions, including a potential high‑share contender large observational study reporting new side effects such as hair loss and mixed public reactions. Despite heightened market activity, Lilly remains focused on completing manufacturing and quality‑control verifications before filing for FDA approval in the expanding weight‑loss market. 2027.